Abstract:Background: Benign multiple sclerosis (BMS) is a controversial term that has been used for MS patients with minimal disability decades after disease onset. Herein, we evaluated disease status after 20 years in a Western Australian cohort defined as BMS based on an Expanded Disability Status Scale (EDSS) score <= 3.0 at 10 years from onset. Methods: MS patients with an EDSS score <= 3.0 at 10 years from onset and minimum of 20 years follow up were included in the study. The 20-year EDSS score was considered the primary outcome. Associations with demographic and clinical characteristics and HLA-DRB1 genotype were investigated. Results: Among 120 patients with a benign course at 10 years, 78 (65%) remained benign at the 20-year follow up, but patients with an EDSS >= 2.5 were more likely to go on to develop more severe disability in the next decade. When considering factors associated with an increase in EDSS score <= 1 from 10 to 20 years, indicating limited progression, apart from the EDSS score at 10 years, poly-symptomatic presentation (p = 0.004) and cerebellar/brainstem mono-symptomatic presentation (p = 0.016) were independently associated with more rapid progression compared with other mono-symptomatic presentations. Carriage of the high risk HLA-DRB1*1501 allele was marginally associated with slower progression. Conclusions: In this geographically isolated MS cohort of predominantly Anglo-Celtic origin clinical progression in the benign MS group was similar to that in other published series from Western countries. These results are in keeping with the view that patients labeled as benign MS are part of a heterogeneous continuum of disease progression and do not possess unique clinical characteristics. Possible genetic determinants of a benign course warrant further investigation.

The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort.

The Influence of Non-Hla Gene Polymorphisms and Interactions on Disease Risk in a Western Australian Multiple Sclerosis Cohort

Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study.

Effect of Polymorphism on IL1A to Cancer Susceptibility: Evidence Based on 34,016 Subjects

34. Frequency of HLA-DRB1 Alleles and Disease-Modifying Effects in a Large West Australian Multiple Sclerosis Cohort

Modifying Effects of Hla-Drb1 Allele Interactions on Age at Onset of Multiple Sclerosis in Western Australia

The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility

HLA-DR Allele Polymorphism and Multiple Sclerosis in Chinese Populations: a Meta-Analysis

Meta-analysis of the Selected Genetic Variants in Immune-Related Genes and Multiple Sclerosis Risk

Association of polymorphism 1188A/C of interleukin-12B gene with multiple sclerosis

Four FCRL3 Gene Polymorphisms (FCRL3_3, _5, _6, _8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study

DNA methylation as a mediator of HLA-DRB1*15 : 01 and a protective variant in multiple sclerosis

Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population

Dna Methylation As A Mediator Of Hla-Drb1(Star)15:01 And A Protective Variant In Multiple Sclerosis

Natural History of Benign Multiple Sclerosis: Clinical and HLA Correlates in a Western Australian Cohort

CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis.

Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel Multiple Sclerosis Risk Genes

Association of polymorphism 1188A/C of interlenkin-12B gene with multiple sclerosis

Human Leukocyte Antigen Susceptibility Genes in Multiple Sclerosis

Association between the CD24 Ala57Val polymorphism and risk for multiple sclerosis and systemic lupus erythematosus: a meta-analysis

IL2RA Allele Increases Risk of Neuromyelitis Optica in Southern Han Chinese.